Abstracts tagged "rheumatoid arthritis"

Abstract Number: LB05 • ACR Convergence 2025
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
yujie cai, Nanfang hospital, Guangzhou, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial inflammation and joint bone destruction. Endoplasmic reticulum (ER) stress plays an important role…
Abstract Number: LB15 • ACR Convergence 2025
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
Claire Immediato Daien¹, Jean-Pierre Hellier², Zübeyir Salis³, Gaël Mouterde⁴, Jacques Morel⁵, Laurence Macia⁶ and Rachel audo⁴, ¹CHU and Univesrity of Montpellier, Montpellier, France, ²CHU Montpellier, Arles, France, ³University of Montpellier, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵CHU and University of Montpellier, Montpellier, France, ⁶Sydney University, Brisbane, Australia
Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B.…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Minna Kohler¹, Sally Arai², Fawad Aslam³, Gregory Challener⁴, Matthew Frigault⁴, Melissa Griffith⁵, Tamiko Katsumoto⁶, Elena Massarotti⁷, Larry Moreland⁸, Allison Rosenthal⁹, Jeffrey Sparks⁷, Janeth Yinh⁴, Sarah Baxter¹⁰, Ari Bitton¹¹, Jason Dubovsky¹², Victor Yuan¹³, Mindy Jensen¹⁴, Andrew Clauw¹⁵, Gabrielle Furman⁴, Rita Gyurko⁷, Megan Hall⁹, Anna McIntyre⁴, Jennifer Seifert¹⁶, Emma Stainton², Michelle Blake¹⁰, Sabrina Fox-Bosetti¹³, Herve Lebrec¹³, Amanda Pace¹⁰, Yuanyuan Xiao¹⁷, Mei-Lun Wang¹⁸, Joe Arron¹³ and Jeffrey Bluestone¹⁹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ²Stanford, Palo Alto, California, ³Mayo Clinic, Arizona, Scottsdale, Arizona, ⁴Massachusetts General Hospital, Boston, Massachusetts, ⁵University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁶Stanford University, Millbrae, California, ⁷Brigham and Women's Hospital, Boston, Massachusetts, ⁸University of Colorado, Denver, Colorado, ⁹Mayo Clinic, Phoenix, Arizona, ¹⁰Sonoma Biotherapeutics, Seattle, Washington, ¹¹Sonoma Biotherapeutics, San Diego, California, ¹²Sonoma Biotherapeutics, Thousand Oaks, California, ¹³Sonoma Biotherapeutics, South San Francisco, California, ¹⁴Sonoma Bio, Seattle, Washington, ¹⁵University of Colorado, Aurora, Colorado, ¹⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, ¹⁷Sonoma Biotherapeutics, Los Altos, California, ¹⁸Sonoma Biotherapeutics, San Francisco, California, ¹⁹Sonoma Biotherapeutics Inc, South San Francisco, California
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
Abstract Number: 0433 • ACR Convergence 2025
In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
John Langley¹, Karuna Bista², Clarisse Yapp², Nisha Sapkota³, Shukranta Shrestha² and Sulav Pyakurel¹, ¹Montefiore New Rochelle Hospital, New Rochelle, NY, ²Montefiore New Rochelle Hospital, New Rochelle, ³Interfaith Medical Center, One Brooklyn Health, Brooklyn, NY
Background/Purpose: Although it has been documented that patients with Rheumatoid Arthritis may be at increased risk of Pulmonary Embolism, other inpatient outcomes remain largely unexplored.…
Abstract Number: 0265 • ACR Convergence 2025
Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis
Mohammed Mohammed¹, Bindee Kuriya², Lihi Eder¹, Elsie Nguyen³, Shadi Ahktari⁴, Paula Harvey⁵, Wei Wu⁶ and Sohan Shahab⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, Canada, ⁷Women’s College Research Institute, Women’s College Hospital, Toronto, Canada
Background/Purpose: Patients with inflammatory arthritis (IA) have increased cardiovascular risk. Coronary artery calcium (CAC) scoring by computed tomography (CT) detects early coronary disease and structural…
Abstract Number: 0168 • ACR Convergence 2025
Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Liya Sisay Getachew⁶, Mark Chaballa⁷, Vadim Khaychuk⁸, Misti Paudel⁹, Katherine Liao¹⁰ and Jeffrey Sparks⁶, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Pennington, NJ, ⁹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), is a serious extra-articular manifestation of RA that significantly contributes…
Abstract Number: 0088 • ACR Convergence 2025
Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
Lyndsey Cole¹, Brendan Allen², Sucai Liu², Marie Feser³, Le Yi Phyo², LauraKay Moss², Daniel Frank², J. Kirk Harris², Kristen Demoruelle⁴, Kevin Deane⁵, V. Michael Holers⁶ and Kristine Kuhn⁷, ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁶University of Colorado Anschutz Medical Campus, Aurora, ⁷²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: The mucosal origins hypothesis of RA proposes that immune responses to microorganisms at mucosal sites (e.g. intestine) lead to systemic inflammation and autoimmunity. Little…
Abstract Number: 0068 • ACR Convergence 2025
Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
Aryan Patel¹, Osama Al Zoubi² and Shiva Shahrara³, ¹University of Illinois at Chicago, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³University of Illinois, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: 2643 • ACR Convergence 2025
Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
Rahul Bodkhe¹, Kai Trepka¹, Diego Orellana¹, Rebecca Blank², Peter Turnbaugh³, Jose Scher⁴ and Renuka Nayak⁵, ¹University of California San Francisco, San Francisco, CA, ²NYU Langone Health, New York, NY, ³University of California, San Francisco, San Francisco, CA, ⁴New York University School of Medicine, New York, NY, ⁵University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a common systemic autoimmune disease that targets the joints, causing persistent pain and swelling. Oral methotrexate (MTX) remains first-line therapy…
Abstract Number: 2419 • ACR Convergence 2025
Dried Blood Spots for Remote ANA and Autoantibody Screening
Miriam Li¹, Paul Sciore², Marvin J. Fritzler³, Ashley Clarke¹, Wrechelle Ocampo¹, katherine Buhler¹, Jeremiah Seni⁴, Lynden Crowshoe¹, Dianne Mosher¹ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²MitogenDx, Calgary, AB, Canada, ³MitognDx, Calgary, AB, Canada, ⁴Catholic University of Health and Allied Sciences, Mwanza, Tanzania
Background/Purpose: Antinuclear antibody (ANA) and SLE-related autoantibody testing are integral parts of SLE screening, diagnosis, and monitoring. However, these tests rely on access to phlebotomy…
Abstract Number: 2276 • ACR Convergence 2025
Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Jennifer Hanberg¹, David Cheng², Xuan Wang³, Rahul Sangar⁴, Yuk-Lam Ho⁴, Lauren Costa⁴, Rachael Matty⁴, Candace Feldman¹, Tate Johnson⁵, Joshua Baker⁶, Bryant England⁵, J. Michael Gaziano¹, Kelly Cho⁷, James O'Dell⁵, Grant Cannon⁸, Paul Monach⁴, Ted Mikuls⁵, Tianxi Cai⁷ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³University of Utah, Salt Lake City, UT, ⁴VA Boston Healthcare System, Boston, MA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Harvard Medical School, Boston, MA, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are often avoided when treating rheumatoid arthritis (RA) patients with decompensated heart failure (HF), based on increased rates of…
Abstract Number: 2261 • ACR Convergence 2025
Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India
Sryla Punjadath¹, Venkatesh Srinivasa Pai¹, Prativa Priyadarshani Sethi¹, ritu sangwan², Abhishek Rai³ and Ravi Kant¹, ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ³AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Palindromic Rheumatism (PR) is recognized as a clinical syndrome of intermittent episodes of pain, swelling, and erythema in and around joints, which are severe…
Abstract Number: 2244 • ACR Convergence 2025
Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
Kei Hirose¹, Keigo Hayashi², Natsuki Kubota², Yuya Terajima², Kazuya Matsumoto², Takato Nakadoi², Shoichi Nawachi², Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama², Haruki Watanabe², Mariko Narazaki², Yoshinori Matsumoto² and Jun Wada², ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a well-established risk factor for fractures, due to both systemic inflammation and treatment-related effects on bone metabolism. This study aimed…

1
2
3
…
219
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].